Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma.

Paweł SobczukMichał CholewińskiPiotr Lukasz Rutkowski

Published in: Expert opinion on pharmacotherapy (2024)

-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.

Keyphrases

vascular endothelial growth factor
small molecule
chronic myeloid leukemia
skin cancer
tyrosine kinase
high throughput
advanced non small cell lung cancer
basal cell carcinoma
case control
wild type
single cell
endothelial cells
replacement therapy